Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Eli Lilly (NYSE:LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday.  The ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...